Five years of innovation
in discovery science

The UK’s leading biomedical research institute
dedicated to neurodegenerative diseases

Watch film

Our research

See how our science is tackling dementia

Lab profiles

Our teams are growing

Come join us in transforming dementia research

Vacancies
Cfba Walking Bridge
News

New £20m Dementia Trials Accelerator will increase number of dementia trial participants to “tens of thousands”

A new “Dementia Trials Accelerator”, backed by £20m of government funding and spearheaded by the UK DRI and Health Data Research UK, has been launched to increase the number of people participating in dementia clinical trials in the UK from just 61 in 2021-22 to “tens of thousands”.

Read more
I Psc Mns Copy
World Alzheimer's Month

Developing new treatments for FTD and ALS: a bumpy road to success

In this article Prof Adrian Isaacs (UK DRI at UCL) discusses his research journey, what he has learned from setbacks, the success of his project harnessing the fruit fly and why the support of the UK DRI has been invaluable to his lab’s development.

Read more
Joanna Wardlaw
World Alzheimer's Month

Repurposing cheap and common drugs to treat cerebral small vessel disease

Prof Joanna Wardlaw (UK DRI at Edinburgh) is setting up the first phase III trial in cerebral small vessel disease aimed at improving cognitive symptoms by repurposing two drugs.

Read more

Keep in touch with UK DRI activities

Sign up to our monthly e-newsletter - 'Inside Eye on UK DRI'

Subscribe
Older Lady Concerned Shutterstock Fizkes
News

MHRA approves lecanemab but NICE deems drug not cost effective for use on NHS

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved lecanemab for use in the UK to treat early-stage Alzheimer’s disease. However, draft guidance released simultaneously by NICE, has said that the benefits of the new drug are too small to justify the costs, and therefore has not recommended it for availability on the NHS. Here, UK DRI researchers respond to the news.

Read more
Better Ageing
Report

Lancet Commission report finds nearly half of dementia cases could be prevented or delayed

The Lancet Commission on dementia prevention, intervention and care, concludes that addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases. Here, UK DRI researchers respond to the new report.

Read more
Friends Of Crt Event Dan Weill Photography 24
Get involved

Friends of CR&T: A new network to shape dementia research

The UK DRI exists to improve the lives of people affected by dementia. By involving people who have lived experience in our research, we can ensure new treatments and technologies meet the needs of those affected.

Read more

Discovering hope
for dementia

Find out how we are leading the
journey of discovery in dementia

Read more
Alzheimers Care
Translation and innovation

Turning breakthroughs into treatments

We have a clearly defined vision at the UK DRI to develop effective therapeutics, diagnostics and technologies for people living with dementia. Alongside building our disease knowledge over the coming years, we will also make progress in translating these discoveries into the clinic.

Translation and innovation
Barnes Mouse Hippocampus Smaller
Science Vision

Our priorities as a research institute

We accelerate, innovate, deepen and broaden discovery science in dementia, with the goal of filling the huge knowledge gap in this field. We exist to bring forward the day when research benefits people living with and those at risk of dementia.

Read our science vision
Connectome Crowd Red
Equity, Diversity and Inclusion

Collaboration and connection

Our efforts to increase the diversity of our team, ensure inclusion and promote equality of opportunity, align with our vision for the UK DRI’s Institute culture and identity as a world-leader in dementia research.

Equity, Diversity and Inclusion
Themes Pin In Board Red
Research themes

Bringing together researchers to address major scientific questions

We study a range of neurodegenerative disorders that cause dementia. Many of them share fundamental disease mechanisms and characteristics, and greater understanding gained in one can often benefit others. To ensure we capitalise on diverse expertise, approaches and perspectives, we have established cross-centre themes.

Research themes